New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
11:28 EDTMDCOThe Medicines Co. briefing documents mixed, says Jefferies
Jefferies views the briefing documents for The Medicines Co.'s cangrelor as mixed with one reviewer recommending against approval and one for approval. The firm thinks the dose and timing of the loading dose will be a key topic of discussion at the advisory meeting on Wednesday and keeps a Buy rating on The Medicines Co.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
10:01 EDTMDCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 58.com (WUBA) upgraded to Buy from Hold at Summit Research... Altria Group (MO) upgraded to Buy from Outperform at CLSA... Ares Commercial (ACRE) upgraded to Outperform from Market Perform at FBR Capital... BAE Systems (BAESY) upgraded to Overweight from Equal Weight at Morgan Stanley... BGC Partners (BGCP) upgraded to Strong Buy from Outperform at Raymond James... Cognizant (CTSH) upgraded to Buy on valuation at CLSA... Edwards Lifesciences (EW) upgraded to Overweight from Equal Weight at Morgan Stanley... Guess (GES) upgraded to Neutral from Underweight at Piper Jaffray... MarkWest Energy (MWE) upgraded to Overweight from Equal Weight at Barclays... Palo Alto (PANW) upgraded to Outperform following checks at Cowen... The Medicines Co. (MDCO) upgraded to Buy from Neutral at Mizuho... TripAdvisor (TRIP) upgraded to Equal Weight from Underweight at Barclays... Union Pacific (UNP) upgraded to Outperform at Cowen... United Continental (UAL) upgraded to Buy from Fair Value at CRT Capital... eHealth (EHTH) upgraded on Medicare outlook, risk/reward at RBC Capital.
06:46 EDTMDCOThe Medicines Co. upgraded to Buy from Neutral at Mizuho
Mizuho upgraded The Medicines Co. to Buy and raised its price target to $41 following last week's negative appeals court verdict that leads the way for Angiomax generics near-term. The firm believes consensus estimates still need to come down but believes an overhang has been removed and the focus should be on the company's many new launches and developmental compounds and collaboration potential.
06:41 EDTMDCOEagle Pharmaceuticals price target raised to $94 from $75 at Piper Jaffray
Subscribe for More Information
July 2, 2015
13:19 EDTMDCOCantor lowers sales assumptions for Eagle's Angiomax version
After an appeals court invalidated the Angiomax patents held by The Medicines Company (MDCO), Cantor Fitzgerald lowered its price target for Eagle Pharmaceuticals (EGRX) to $92 from $95 to reflect more modest sales assumptions for the company's version of Angiomax. Cantor had previously modeled a more favorable for Eagle whereby there were no generic entrants until 2019. The firm, however, still sees the stock as undervalued and keeps a Buy rating on the name.
12:40 EDTMDCOMedicines Co. says appeals court rules against company in Angiomax litigation
Subscribe for More Information
10:17 EDTMDCOAppeals court reverses lower court patent ruling in Medicines Co. case
The Medicines Company (MDCO) owns U.S. patent no. 7,582,727 and U.S. patent no. 7,598,343, which relate to the drug bivalirudin, a synthetic peptide used as an anti-coagulant that the company sells under the Angiomax brand. On August 19, 2010, The Medicines Company sued Hospira (HSP), alleging that two of Hospira’s ANDA filings infringe claims 1–3, 7–10, and 17 of the ’727 patent and claims 1–3 and 7–11 of the ’343 patent. A district court previously construed the asserted claims and, after a bench trial, found the patents not infringed and not invalid as obvious, indefinite, or under the on-sale bar. The Medicines Company appealed the U.S. District Court for the District of Delaware’s claim construction and non-infringement findings, while Hospira, crossappealed the district court’s determination that the asserted claims are not invalid under the on-sale bar, obviousness, or indefiniteness. The U.S. Court of Appeals for the Federal Circuit has now concluded that the district court "clearly erred" in finding that the bivalirudin batches prepared by Ben Venue Laboratories before the critical date were not sold to The Medicines Company and were prepared primarily for an experimental purpose. Accordingly, the federal appeals court reversed the district court’s validity determination and held the asserted claims invalid under the onsale bar. Shares of Medicines Co., which initially fell amid headlines regarding the ruling, are now up 4.5% to $29.61, while Hospira is flat at $88.90.
10:04 EDTMDCOHigh option volume stocks
Subscribe for More Information
09:57 EDTMDCOMedicines Co. loses appeal in Hospira suit over Angiomax patents, Bloomberg says
Subscribe for More Information
09:50 EDTMDCOThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
June 26, 2015
07:15 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg reports
The Medicines Co. is working with advisers from Rothschild on a review of strategic options for its European business, according to Bloomberg, citing people familiar with the matter. The review, which is at an advanced stage, may lead to a sale, licensing agreement or partnership, the report added. Reference Link
June 25, 2015
14:38 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg says
June 22, 2015
16:37 EDTMDCOThe Medicines Co. to hold a conference call
Subscribe for More Information
14:33 EDTMDCOThe Medicines Co. antiplatelet drug approved by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use